Protocol Details

Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	97-C-0147
Sponsoring Institute	National Cancer Institute (NCI)
Recruitment Detail	Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 2 Years Max Age: N/A
Referral Letter Required	No
Population Exclusion(s)	None
Keywords	Serum; Collection of Tissue; Malignant Disease; Molecular Basis; Genome Sequencing; Natural History
Recruitment Keyword(s)	None
Condition(s)	Malignant Neoplasms; Hereditary Neoplastic syndromes; Kidney Cancer; Renal Cancer; Bladder Cancer
Investigational Drug(s)	None
Investigational Device(s)	None
Intervention(s)	None
Supporting Site	National Cancer Institute

Selected patients suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

- Adult and minor patients with biopsy-proven malignant disease

- Adult and minor patients suspected of having a malignant disease

- Patients who have or are suspected of having an inherited genitourinary malignant disorder

- Participants must be >= 2 years of age

- Family members (related by blood) of patients who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder.

-All patients and guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. Patients under the age of 18 but who are age 13 or older will be asked to sign an assent document prior to participation.

EXCLUSION CRITERIA:

- Subjects whose co-morbidities preclude surgical intervention.

--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information:
W. Marston Linehan, M.D. National Cancer Institute (NCI) NIHBC 10 - CRC BG RM 1-5942 10 CENTER DR BETHESDA MD 20892 (240) 858-3700 linehanm@mail.nih.gov	Deborah A. Nielsen, R.N. National Cancer Institute (NCI) National Institutes of Health Building 10 Room 13N218 10 Center Drive Bethesda, Maryland 20892 (240) 760-6247 deborah.nielsen@nih.gov	NCI Referral Office National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office 1-888-NCI-1937 ncimo_referrals@mail.nih.gov

Clinical Trials Number:

NCT00026884

--Back to Top--